0
0
Date: December 8, 2025
SEOUL — For decades, the battle against nicotine addiction has focused almost exclusively on neurons, the brain’s primary electrical transmitters. However, a groundbreaking study published this week has upended that paradigm. Researchers at Pusan National University in South Korea have identified a specific brain enzyme, glutamine synthetase, located not in neurons but in “support” cells known as astrocytes, as a critical driver of nicotine dependence.
The findings, published in the December issue of Nature Neuroscience and highlighted by MedicalXpress, suggest that the path to effective smoking cessation treatments may lie in targeting the brain’s glial cells—specifically astrocytes—rather than just the neuronal circuits traditionally associated with reward and craving.
The ‘Overlooked’ Architect of Addiction
The study, led by Professor Choe Motoyuki and his team at Pusan National University, reveals that astrocytes are far more than passive bystanders in the brain. While long thought to merely provide structural support and nutrients to neurons, the research demonstrates that these star-shaped cells actively regulate the neurochemical environment that fosters addiction.
“We have historically viewed addiction as a conversation between neurons, mediated by dopamine,” said Prof. Choe in a press statement. “Our research shows that astrocytes are the conductors of this orchestra. When nicotine enters the brain, it doesn’t just tickle neurons; it aggressively stimulates receptors on astrocytes, triggering a cascade that reinforces dependency.”
Key Findings: The Calcium-Enzyme Connection
The research team utilized advanced imaging and molecular manipulation in rat models to map the mechanism. They discovered that nicotine exposure stimulates nicotinic acetylcholine receptors (nAChRs) located on the surface of astrocytes.
This stimulation triggers a massive surge of intracellular calcium within the astrocyte. This calcium spike, in turn, activates glutamine synthetase, an enzyme responsible for converting glutamate (a potent excitatory neurotransmitter) into glutamine.
“The over-activation of glutamine synthetase alters the balance of excitatory and inhibitory signals in the brain,” the study reports. “This chemical shift effectively ‘locks in’ the locomotor sensitization and craving behaviors associated with nicotine withdrawal.”
Crucially, when the researchers used a targeted inhibitor to block the activity of glutamine synthetase specifically in the astrocytes of nicotine-dependent rats, the animals showed a significant reduction in drug-seeking behavior and withdrawal symptoms.
Expert Perspectives
The shift in focus from neurons to astrocytes has generated significant buzz in the neurobiology community.
“This is a potential game-changer,” said Dr. Elena Rossi, a neuropharmacologist at the Scripps Research Institute who was not involved in the study. “For years, we’ve developed drugs that target neuronal receptors, often with limited success or significant side effects because those receptors are ubiquitous. Targeting an enzymatic process within astrocytes offers a novel, and perhaps more precise, therapeutic avenue.”
However, Dr. Rossi cautioned that the transition from animal models to human application is complex. “Astrocytes perform critical maintenance functions. We need to ensure that inhibiting glutamine synthetase to treat addiction doesn’t disrupt normal brain metabolism or memory consolidation.”
Public Health Implications
Despite the global decline in smoking rates—projected to hit approximately 18% in South Korea and similar lows in Western nations by 2025—nicotine addiction remains a stubborn public health crisis. The rise of synthetic nicotine pouches and high-potency vaping devices has introduced new generations to dependence.
Current cessation aids, such as nicotine replacement therapy (NRT) and varenicline (Chantix), target neuronal receptors directly. While effective for some, relapse rates remain high, often exceeding 70% in the first year.
“If we can develop a drug that dampens this astrocytic enzyme activity,” explains Dr. Marcus Thorne, a clinical addiction specialist at London’s Maudsley Hospital, “we might be able to reduce the physical ‘pull’ of addiction without blunting the brain’s natural reward system, which is a common complaint with current medications.”
Limitations and Future Research
While promising, the study has limitations. It was conducted on rodent models, and the human brain’s astrocytic complexity is far greater. Furthermore, glutamine synthetase is vital for removing excess glutamate, which can be toxic to neurons if left unchecked. Any therapeutic intervention would need to modulate, not eliminate, the enzyme’s activity to avoid neurotoxicity.
The Pusan National University team has announced plans for follow-up studies to identify compounds that can selectively downregulate this pathway in human brain organoids, with hopes of entering early-stage clinical trials by 2027.
Conclusion
As the medical community digests these findings, one thing is clear: the model of addiction as solely a “neuronal disease” is obsolete. By shining a light on the brain’s “support staff,” scientists may have finally found the blueprint for breaking the chains of nicotine dependence.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
News Source: Pusan National University via MedicalXpress. (2025, December 4). “Brain enzyme that drives nicotine addiction and smoking dependence identified.” Retrieved from https://medicalxpress.com/news/2025-12-brain-enzyme-nicotine-addiction.html
